Studying AZD0901 for Claudin18.2-positive advanced solid tumors
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called AZD0901 for people with advanced solid tumors that have a specific protein on their surface. It aims to see if the drug can shrink or slow the growth of these tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older at the time of signing up.
- Your tumor must have a specific protein called Claudin18.2.
- You must have at least one tumor that can be measured on a scan.
- You must be able to do daily activities with little or no help (ECOG 0-1).
- You cannot have had a certain type of targeted chemo (MMAE-based ADC) or treatment targeting Claudin18.2 before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests new combination treatments for advanced stomach or stomach-esophagus junction cancer that cannot be removed by surgery. It may help people whose tumors are positive for a marker called Claudin18.2, which the study uses to choose who can receive the treatment.
This trial tests a new medication that targets a specific protein (CLDN18.2) found on some cancer cells. It may help people with advanced or metastatic stomach, esophageal, or pancreatic cancer who have already tried other treatments.
This trial is testing a new combination of drugs (osemitamab, pembrolizumab, and chemotherapy) as the first treatment for advanced stomach cancer. It's for people whose tumors have a specific marker called Claudin 18.2, which might make the treatment more effective.
This study tests new drug combinations for people with various advanced cancers that have progressed after standard treatment, or in some cases, as a first treatment. It aims to see if these combinations are safe and effective. The study is divided into groups based on cancer type and treatment history, so not everyone will qualify for every group.
This trial is testing a new medicine, AZD9793, for people with advanced or metastatic solid tumors that have a specific marker called GPC3. The goal is to see if AZD9793 can help shrink or control the cancer.
This trial tests a new drug called AZD6750 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.